Novel HDAC inhibitors with radiosensitizing properties

Radiation Research

Volumn 163, Issue 5, 2005, Pages 488-493

  Jung, Mira ^a,c   Velena, Alfredo ^a   Chen, Bin ^b   Petukhov, Pavel A ^b   Kozikowski, Alan P ^b   Dritschilo, Anatoly ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; UREA; ENZYME INHIBITOR; RADIOSENSITIZING AGENT;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TYPE; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOSENSITIZATION; TRANSCRIPTION REGULATION; DRUG ANTAGONISM; DRUG EFFECT; RADIATION DOSE; TUMOR CELL LINE;

CELL LINE, TUMOR; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

EID: 19444376297     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR3345     Document Type: Article

References (29)

1. M. Grunstein, Histone acetylation in chromatin structure and transcription. Nature 389, 349-352 (1997).
2. R. T. Utley, K. Ikeda, P. Grant, J. Cote, D. Steger, A. Eberhater, S. John and J. Workman, Transcriptional activators direct histone acetyltransferase complexes to nucleosomes. Nature 394, 498-502 (1998).
3. A. J. Bannister and T. Kouzarides, The CBP co-activator is a histone acetyltransferase. Nature 38, 641-643 (1996).
4. K. Struhl and Z. Moqtaderi, The TAFs in the HAT. Cell 94, 1-4 (1998).
5. A. J. De Ruijter, A. H. Van Gennip, H. N. Caron, S. Kemp and A. B. Van Kuilenburg, Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem. J. 370, 737-749 (2003).
6. I. Gregoretti, Y. M. Lee and H. V. Goodson, Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. J. Mol. Biol. 338, 17-31 (2004).
7. W. Fischle, V. Kiermer, F Dequiedt and E. Verdin, The emerging role of class II histone deacetylases. Biochem. Cell Biol. 79, 337-348 (2001).
8. P. Marks, R. A. Rifkind, V. M. Richon, R. Breslow, T. Miller and W. K. Kelly, Histone deacetylases and cancer: Causes and therapies. Nat. Rev. Cancer 1, 194-202 (2001).
9. L. M. Butler, D. B. Agus, H. I. Scher, B. Higgins, A. Rose, C. Cordon-Cardo, H. T. Thaler, R. A. Rifkind, P. A. Marks and V. M. Richon, Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60, 5165-5170 (2000).
10. J. Gilbert, S. D. Baker, M. K. Bowling, L. Grochow, W. D. Figg, Y. Zabelina, R. C. Donehower and M. A. Carducci, A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res. 7, 2292-2300 (2001).
11. W. K. Kelly, V. M. Richon, O. O'Conner, T. Curley, B. MacGregor-Curtelli, W. Tong, M. Klang, L. Schwartz, S. Richardson and H. Scher, Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9, 3578-3588 (2003).
12. V. Sander, S. Bakk, R. W. Robey and M. H. Kang, Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8, 718-728 (2002).
13. L. M. Butler, Y. Webb, D. B. Agus, B. Higgins, T. R. Tolentino, M. C. Kutko, M. P. LaQuaglia, M. Drobnjak, C. Cordon-Cardo and P. A. Marks, Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin. Cancer Res. 7, 962-970 (2001).
14. M. Gottlicher, S. Minucci, P. Zhu, O. H. Kramer, A. Schimpf, S. Giavara, J. P. Sleeman, F. Lo Coco, C. Nervi and T. Heinzel, Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969-6978 (2001).
15. X. Yu, Z. S. Guo, M. G. Marcu, L. Neckers, D. M. Nguyen, C. A. Chen and D. S. Schrump, Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. 94, 504-513 (2002).
16. O. H. Kramer, P. Zhu, H. P. Ostendorff, M. Golebiewski, J. Tiefenbach, M. A. Peters, B. Brill, B. Groner, I. Bach and M. Gottlicher, The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO 22, 3411-3420 (2003).
17. R. R. Weichselbaum, D. E. Hallahan, V. Sukhatme, A. Dritschilo, M. Sherman and D. Kufe, Biological consequences of gene regulation by ionizing radiation. J. Natl. Cancer Inst. 83, 480-484 (1991).
18. Y. Zhang, A. Dimtchev, A. Dritschilo and M. Jung, Ionizing radiation-induced apoptosis in ataxia telangiectasia fibroblasts: Roles of caspase-9 and cellular inhibitor of apoptosis protein-1. J. Biol. Chem. 276, 28842-28848 (2001).
19. C. M. Arundel, A. S. Glicksman and J. T. Leith, Enhancement of radiation injury in human colon tumor cells by the maturational agent sodium butyrate (NaB). Radiat. Res. 104, 443-448 (1985).
20. S. Biade, C. C. Stobbe, J. T. Boyd and J. D. Chapman, Chemical agents that promote chromatin compaction radiosensitize tumor cells. Int. J. Radiat. Biol. 77, 1033-1042 (2001).
21. Y. Zhang, M. Jung, A. Dritschilo and M. Jung, Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat. Res. 161, 667-674 (2004).
22. G. D. Kim, Y. H. Choi, A. Dimtchev, S. J. Jeong, A. Dritschilo and M. Jung, Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase. J. Biol. Chem. 274, 31127-31130 (1999).
23. R. Ju and M. T. Muller, Histone deacetylase inhibitors activate p21 (WAF1) expression via ATM. Cancer Res. 63, 2891-2897 (2003).
24. G. D. Kao, W. G. McKenna, M. G. Guenther, R. J. Muschel, M. A. Lazar and T. J. Yen, Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J. Biol. Chem. 160, 1017-1027 (2003).
25. N. Albright, Computer programs for analysis of cellular survival data. Radiat. Res. 112. 331-340 (1987).
26. R. Furumai, Y. Komatsu, N. Nishino, S. Khochbin, M. Yoshida and S. Horinouchi, Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA 98, 87-92 (2001).
27. N. Mishra, C. M. Reilly, D. R. Brown, P. Ruiz and G. S. Gilkeson, Histone deacetylase inhibitors modulate renal disease in the MRL-Ipr/Ipr mouse. J. Natl. Cancer Inst. 111, 539-552 (2003).
28. E. Hockly, V. M. Richon, B. Woodman, D. L. Smith, X. Zhou, E. Rosa, K. Sathasivam, S. Ghazi-Noori, A. Mahal and G. P. Bates, Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA 100, 2041-2046 (2003).
29. S. D. Gore, L. J. Weng, W. D. Figg, S. Zhai, R. C. Donehower, G. Dover, M. R. Grever, C. Griffin, L. B. Grochow and C. B. Miller, Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 63, 963-970 (2002).